Table of Contents
Metal-Based Drugs
Volume 2008, Article ID 417897, 15 pages
Review Article

Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism

1Department of Cytokinetics, Institute of Biophysics, Královopolská 135, Brno 612 65, Czech Republic
2Department of Vaccinology and Immunotherapy, Veterinary Research Institute, Hudcova 70, Brno 621 00, Czech Republic

Received 30 May 2007; Revised 8 October 2007; Accepted 18 October 2007

Academic Editor: Rafael Moreno-Sanchez

Copyright © 2008 Alois Kozubík et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The impressive impact of cisplatin on cancer on one side and severe side effects, as well as the development of drug resistance during treatment on the other side, were the factors motivating scientists to design and synthesize new more potent analogues lacking disadvantages of cisplatin. Platinum(IV) complexes represent one of the perspective groups of platinum-based drugs. In this review, we summarize recent findings on both in vitro and in vivo effects of platinum(IV) complexes with adamantylamine. Based on a literary overview of the mechanisms of activity of platinum-based cytostatics, we discuss opportunities for modulating the effects of novel platinum complexes through interactions with apoptotic signaling pathways and with cellular lipids, including modulations of the mitochondrial cell death pathway, oxidative stress, signaling of death ligands, lipid metabolism/signaling, or intercellular communication. These approaches might significantly enhance the efficacy of both novel and established platinum-based cytostatics.